Replicate Bioscience, a clinical-stage company, announced on Tuesday that it has dosed its first subject in a phase one trial of RBI-4000 vaccine intended to prevent rabies.
This trial is the first time a human has been dosed with the company's srRNA technology and will serve as a benchmark for this purpose and towards preventing other complex infectious diseases.
Nathaniel Wang, PhD, founder and CEO of Replicate, said: "Rabies represents an ideal opportunity to provide rapid clinical validation of our novel vaccine technology given the large exposure-naive population and established correlates for protection as measured by the World Health Organization. Dosing our first participant is a significant milestone for our company as we advance our next generation srRNA technology across several disease areas."
TC BioPharm plans Proof of Concept preclinical studies of TCB 008 for treatment of monkey pox
LakeShore Biopharma names new chief executive officer
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
RedHill Biopharma launches Talicia in UAE for H. pylori treatment
RedHill Biopharma reports promising results for opaganib in obesity and diabetes studies
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI
Technavio predicts increase in global peptide therapeutics market size